PE20250558A1 - Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno - Google Patents

Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno

Info

Publication number
PE20250558A1
PE20250558A1 PE2023002494A PE2023002494A PE20250558A1 PE 20250558 A1 PE20250558 A1 PE 20250558A1 PE 2023002494 A PE2023002494 A PE 2023002494A PE 2023002494 A PE2023002494 A PE 2023002494A PE 20250558 A1 PE20250558 A1 PE 20250558A1
Authority
PE
Peru
Prior art keywords
compounds
disorders
treatment
alkyl
procedure
Prior art date
Application number
PE2023002494A
Other languages
English (en)
Spanish (es)
Inventor
Zaneti De Azevedo Hatylas Felype
Torres Russo Valter Freire
De Souza Russo Elisa Mannochio
Alessandra Mascarello
Da Costa Renata Watanabe
Werneck Guimarães Cristiano Ruch
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of PE20250558A1 publication Critical patent/PE20250558A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PE2023002494A 2016-10-24 2017-10-23 Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno PE20250558A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102016024814A BR102016024814A2 (pt) 2016-10-24 2016-10-24 composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
PCT/BR2017/050320 WO2018076090A1 (en) 2016-10-24 2017-10-23 Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders

Publications (1)

Publication Number Publication Date
PE20250558A1 true PE20250558A1 (es) 2025-02-24

Family

ID=62023150

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2023002494A PE20250558A1 (es) 2016-10-24 2017-10-23 Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno
PE2019000861A PE20191046A1 (es) 2016-10-24 2017-10-23 Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2019000861A PE20191046A1 (es) 2016-10-24 2017-10-23 Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno

Country Status (20)

Country Link
US (2) US10781182B2 (enExample)
EP (2) EP3529234B1 (enExample)
JP (1) JP7194683B2 (enExample)
KR (1) KR102594251B1 (enExample)
CN (2) CN115181108A (enExample)
AR (1) AR109467A1 (enExample)
AU (1) AU2017351756B2 (enExample)
BR (1) BR102016024814A2 (enExample)
CL (1) CL2019001105A1 (enExample)
CO (1) CO2019004756A2 (enExample)
DK (1) DK3529234T3 (enExample)
EC (1) ECSP19032963A (enExample)
ES (2) ES2970546T3 (enExample)
FI (1) FI3529234T3 (enExample)
MX (1) MX392990B (enExample)
PE (2) PE20250558A1 (enExample)
PT (1) PT3529234T (enExample)
SG (2) SG11201903113TA (enExample)
UY (2) UY40644A (enExample)
WO (1) WO2018076090A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3640251T (lt) 2016-10-24 2022-03-10 Astrazeneca Ab 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
MX2019008438A (es) 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
AR121842A1 (es) * 2020-04-15 2022-07-13 Ache Laboratorios Farmaceuticos Sa Compuesto de benzimidazol para el tratamiento de trastornos metabólicos
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
JP7719796B2 (ja) 2020-04-24 2025-08-06 アストラゼネカ・アクチエボラーグ 医薬製剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5260051A (en) 1990-12-17 1993-11-09 Lever Brothers Company, Division Of Conopco, Inc. Compositions comprising phosphate ester compounds containing a beneficial reagent component
FR2674524B1 (fr) 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
US6376666B1 (en) * 1994-06-10 2002-04-23 Nauchno-Issledovatelsky Institut Farmakologii Rossiiskoi Akademii Meditsinskikh Nauk 2-mercaptobenzimidazole derivatives possessing pharmacological activity
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
FR2738818B1 (fr) 1995-09-18 1997-12-05 Valentonine Nouveaux derives d'oxydation d'indolylalkylamines, et leur utilisation a titre de medicament
US6034239A (en) 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) * 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
ZA9711051B (en) 1996-12-10 1999-06-09 Bristol Myers Squibb Co Benzodioxole benzofuran dihydrobenzofuran and benzodioxane melatonergic agents
CA2334299A1 (en) 1998-06-05 1999-12-09 Pierre Dextraze Heterocyclic cis cyclopropane derivatives as melatonergic agents
EP1189900B1 (en) 1999-06-30 2004-01-14 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
EP1467986A1 (en) * 2002-01-17 2004-10-20 Eli Lilly And Company Aza-cyclic compounds as modulators of acetylcholine receptors
JPWO2005080334A1 (ja) * 2004-02-23 2007-08-02 大日本住友製薬株式会社 新規ヘテロ環化合物
ES2264641B1 (es) * 2005-06-17 2008-03-01 Quimica Sintetica, S.A. Procedimiento para la obtencion de derivados de bencimidazol y sus intermedios.
WO2008032164A2 (en) * 2006-09-12 2008-03-20 Pfizer Products Inc. Benzimidazolone derivatives
WO2008051533A2 (en) * 2006-10-25 2008-05-02 Takeda Pharmaceutical Company Limited Benzimidazole compounds
RU2401831C2 (ru) * 2008-12-15 2010-10-20 Алла Хем, Ллс Средство, снижающее влечение к алкоголю, фармацевтическая композиция и способы ее получения, лекарственное средство и способ лечения
BR102016024814A2 (pt) * 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono

Also Published As

Publication number Publication date
CN115181108A (zh) 2022-10-14
ES2970546T3 (es) 2024-05-29
EP3741760B1 (en) 2024-12-04
PE20191046A1 (es) 2019-08-06
AU2017351756B2 (en) 2022-01-27
SG11201903113TA (en) 2019-05-30
WO2018076090A1 (en) 2018-05-03
ES3013994T3 (en) 2025-04-16
JP7194683B2 (ja) 2022-12-22
BR112019008197A2 (pt) 2019-07-16
EP3529234B1 (en) 2023-11-29
KR20190066023A (ko) 2019-06-12
US11091445B2 (en) 2021-08-17
FI3529234T3 (fi) 2023-12-28
AR109467A1 (es) 2018-12-12
UY37334A (es) 2018-04-30
MX2019004782A (es) 2019-10-09
CL2019001105A1 (es) 2019-09-06
ECSP19032963A (es) 2019-05-31
PT3529234T (pt) 2024-02-01
CO2019004756A2 (es) 2019-05-21
UY40644A (es) 2024-02-29
DK3529234T3 (da) 2024-02-05
JP2019537624A (ja) 2019-12-26
US20190270711A1 (en) 2019-09-05
MX392990B (es) 2025-03-24
EP3529234A1 (en) 2019-08-28
CA3042040A1 (en) 2018-05-03
AU2017351756A1 (en) 2019-05-09
EP3741760A1 (en) 2020-11-25
CN110088092A (zh) 2019-08-02
CN110088092B (zh) 2022-10-04
EP3529234A4 (en) 2020-03-11
SG10202009001TA (en) 2020-10-29
BR102016024814A2 (pt) 2018-05-08
US10781182B2 (en) 2020-09-22
KR102594251B1 (ko) 2023-10-25
US20200277265A1 (en) 2020-09-03
EP3741760C0 (en) 2024-12-04

Similar Documents

Publication Publication Date Title
PE20250558A1 (es) Compuestos, procedimiento de obtencion de los compuestos, composicion farmaceutica, uso de los compuestos y metodo de tratamiento de desordenes psiquiatricos y/o trastornos del sueno
PE20221010A1 (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2
PE20201165A1 (es) Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY27227A1 (es) Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad
PE20150724A1 (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
AR082428A1 (es) Uso de un compuesto agonista de ep4 para preparar una composicion farmaceutica util para tratar una imperfeccion de la piel y metodos para reparar la piel relacionados
AR076645A1 (es) Derivados isoxazolicos de resorcinol, composiciones farmaceuticas que los comprenden, proceso de sintesis, intermediarios de dicha sintesis y uso de los mismos en trastornos neurodegenerativos y como agentes antitumorales.
AR059621A1 (es) Acidos 4- fenil- tiazol-5- carboxilicos y amidas de acidos 4- fenil- tiazol5 carboxilicos como inhibidores de la plk1
CO2017008809A2 (es) Compuestos de benzoxaborol y uso de los mismos
PE20141940A1 (es) Compuestos triciclicos, composiciones que los comprenden y usos de los mismos
GT200500292A (es) Derivados de 2-amido-4-feniltiazol, su preparacion y su aplicacion en terapeutica
EA201990362A1 (ru) Аналог вортиоксетина и его применение и получение
CR11273A (es) Derivados-2-ona disustituidos en 3, su preparacion y su aplicacion en terapeutica
CL2023003921A1 (es) Inhibidores de transglutaminasas
AR076617A1 (es) Compuestos de aminopirazol triazolotiadiazol inhibidores de la proteina quinasa c-met.
BR112018071548A2 (pt) compostos heterocíclicos bicíclicos substituídos
PE20201148A1 (es) Compuestos biciclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2023015490A (es) Inhibidores de las transglutaminasas.
CL2012001601A1 (es) Compuestos derivados de tiazoles biciclicos, composición farmacéutica; proceso para preparar la composición farmacéutica; kit farmacéutico que los comprende; y su uso en la prevención o tratamiento de enfermedades en las cuales el efecto neuromodulador de los moduladores alostericos de mglur5 es beneficioso.
AR086555A1 (es) Antagonistas de p2x7r y su uso
UY32447A (es) Derivados de 3-benzofuranilindol-2-ona sustituidos en 3, su preparacion y su aplicacion en terapia